Hims & Hers Health, Inc. HIMS
At closeNov 3, 2026, 6:11 PM EST
After hours · Nov 3, 6:11 PM ET
- YTD
- -20.85%
- 1 year
- -42.10%
- Market cap
- 6.00B
- Revenue (ttm)
- 2.58B
- Profit margin
- -5.51%
- EPS (ttm)
- -0.64
- Shares out
- 224.94M
- Forward P/E
- 34.90
- YTD return
- -20.85%
- 1-year return
- -42.10%
- Volume
- 7.34M
- Avg volume
- 10.66M
- Open
- 25.48
- Previous close
- 25.24
- Day's range
- 25.40 – 26.37
- 52-week range
- 13.74 – 48.34
- Beta
- 2.50
- Analysts
- Hold
- Price target
- 31.15 (+21.2%)
- Earnings date
- Nov 9, 2026
2Y +4.94 (+23.80%)
Key statistics
- Enterprise value
- 6.59B
- PEG ratio
- 2.30
- Price / sales
- 2.33
- Price / book
- 18.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 38.20%
- Free cash flow
- 849.44M
- Total cash
- 841.05M
- Total debt
- 1.55B
- Return on equity
- -32.03%
- Short % of float
- 27.55%
- 50-day average
- 28.87
- 200-day average
- 27.00
Analyst view
Consensus: hold
- Target (low)
- 23.00
- Target (mean)
- 31.15
- Target (high)
- 42.00
- Strong buy2
- Buy1
- Hold12
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate 0.15367.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | 0.05663 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.04979 | -0.37 | -0.32 | -643.12% |
| May 11, 2026 | Mar 31, 2026 | 0.02537 | -0.40 | -0.43 | -1,676.67% |
| Feb 23, 2026 | Dec 31, 2025 | 0.02 | 0.07 | +0.05 | +250.00% |
| Nov 3, 2025 | Sep 30, 2025 | 0.09 | 0.06 | -0.03 | -33.33% |
| Aug 4, 2025 | Jun 30, 2025 | 0.18 | 0.17 | -0.01 | -5.56% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 2026 | Truist Securities | main | Hold | Hold |
| Aug 21, 2026 | Barclays | main | Overweight | Overweight |
| Aug 11, 2026 | Citigroup | main | Neutral | Neutral |
| Aug 11, 2026 | Deutsche Bank | main | Hold | Hold |
| Aug 11, 2026 | B of A Securities | main | Neutral | Neutral |
| Aug 11, 2026 | TD Cowen | main | Hold | Hold |
About Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- hims.com
News
3 High Conviction Stocks + Charitable Giving: Tax Alpha With Raul Shah 
HIMS Deadline: HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit 
HIMS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS 
Hims & Hers Health, Inc. (NYSE:HIMS) SHAREHOLDER ALERT: Investors With Losses May Seek to Lead the Class Action in Hims & Hers Health, Inc. Securities Lawsuit - Contact Portnoy Law Firm 
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Hims (NYSE: HIMS) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026 
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law 
DEADLINE ALERT for Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), and Papa John's International, Inc. (PZZA): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions 
HIMS Deadline in 1 Day: Hims & Hers Health, Inc. (NYSE: HIMS) Class Action Lawsuit Seeks Recovery for Investors; November 2, 2026 Deadline- Contact Kessler Topaz Meltzer & Check, LLP 
HIMS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Hims Investors of Securities Class Action Lawsuit Deadline on November 2, 2026 
HIMS FINAL DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS
Your note
Sign in to keep a note on HIMS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAIRD MELISSA | Chief Operating Officer | Conversion of Exercise of derivative security | May 11, 2025 | 805,083 |
| BOUGHTON SOLEIL | Officer | Sale | Oct 27, 2026 | 293,886 |
| CARROLL PATRICK HARRISON | Officer | Conversion of Exercise of derivative security | Aug 13, 2026 | 197,847 |
| CHI MICHAEL Y | Chief Operating Officer | Sale | Sep 14, 2026 | 456,660 |
| DUDUM ANDREW | Chief Executive Officer | Stock Gift | Aug 24, 2026 | 0 |
| ELSHENAWY MOHAMED | Chief Technology Officer | Sale | Sep 14, 2026 | 185,556 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.76% | 28,703,514 | 738.54M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.69% | 10,559,314 | 271.69M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.24% | 9,541,384 | 245.50M | Jun 29, 2026 |
| State Street Corporation | 3.62% | 8,145,699 | 209.59M | Jun 29, 2026 |
| Morgan Stanley | 3.18% | 7,152,498 | 184.03M | Jun 29, 2026 |
| Divisadero Street Capital Management, LP | 2.67% | 6,009,505 | 154.62M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.35% | 7,532,634 | 193.81M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 6,715,813 | 172.80M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.48% | 5,580,591 | 143.59M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.16% | 4,861,892 | 125.10M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.25% | 2,801,108 | 72.07M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.08% | 2,434,622 | 62.64M | Jun 29, 2026 |